How the False Claims Act Applies to Pharmaceutical Companies

The False Claims Act applies to pharmaceutical companies whenever their conduct knowingly causes false or fraudulent claims to be submitted to a federal healthcare program, even though the manufacturer itself rarely bills Medicare or Medicaid directly. The government recovered more than $6.8 billion under the statute in fiscal year 2025, with over $5.7 billion of that coming from the healthcare industry.¹ Drug makers are central to that enforcement because a single marketing or pricing scheme can taint millions of prescription claims across pharmacies, hospitals, and physicians.

What Makes a Drug Company Liable

The False Claims Act (31 U.S.C. §§ 3729–3733) reaches anyone who knowingly submits a false claim for federal payment, or who causes someone else to submit one. Manufacturers almost always fall into the second category. When a company promotes a drug in a way that leads a pharmacy to bill Medicaid for a use the program does not cover, the pharmacy files the claim but the manufacturer is on the hook.²

Liability also extends to making false records that matter to a fraudulent claim, conspiring with others to submit false claims, and — under the “reverse false claim” provision — hanging on to money the company owes back to the government.³

The “Knowingly” Standard

The government does not have to prove specific intent to defraud. “Knowingly” covers actual knowledge, deliberate ignorance, and reckless disregard for the truth.² That is far below the bar for criminal fraud. A company that pushes ahead with a billing or promotional practice while ignoring obvious red flags can be liable even if no executive ever consciously decided to cheat the government.

The Materiality Requirement

Not every regulatory slip creates FCA liability. In Universal Health Services, Inc. v. United States ex rel. Escobar (2016), the Supreme Court held that a false statement or omission must be “material” to the government’s payment decision, meaning it has a natural tendency to influence whether the government pays.⁴ Labeling a rule a “condition of payment” is not enough on its own, and minor noncompliance does not qualify.

Escobar also gave pharmaceutical defendants a useful argument: if the government knew about the noncompliance and kept paying anyway, that is “very strong evidence” the requirement was not material.⁴ Companies increasingly raise this defense where regulators had prior notice through audits or inspections.

The Fraud Schemes That Come Up Repeatedly

Pharmaceutical FCA cases tend to follow a few recurring patterns.

Off-Label Marketing

Doctors may legally prescribe a drug for uses the FDA has not approved. A manufacturer that actively promotes an unapproved use crosses into FCA territory when that promotion causes claims to be submitted to Medicaid or Medicare for uses those programs do not cover.⁵ Off-label cases have produced some of the largest resolutions on record, including GlaxoSmithKline’s $1.8 billion settlement.

Kickbacks to Prescribers

The Anti-Kickback Statute (42 U.S.C. § 1320a-7b) makes it a felony to offer anything of value to induce referrals for services covered by a federal healthcare program. Cash payments, sham consulting fees, expensive dinners, and prescriber travel all qualify. Criminal exposure runs up to $100,000 in fines and 10 years in prison per violation.⁶

What tightens the trap for manufacturers is a 2010 Affordable Care Act amendment. It added subsection (g), which provides that any claim “resulting from” a kickback violation is automatically a false claim under the FCA.⁶ Before that change, the government had to link the kickback to the falsity of the claim. Now the link is built in: if a prescription flowed from an illegal inducement, every claim for that prescription is false.²

Best Price and Rebate Reporting

Manufacturers in Medicaid must report their “best price” — essentially the lowest price offered to any purchaser — so the government captures the most favorable deal. Hiding discounts or rebates given to private buyers understates that figure and causes the government to overpay. These schemes are harder to spot than promotional misconduct because they live inside pricing data, but the losses can be enormous when spread across millions of prescriptions.

Safety, Efficacy, and Manufacturing Fraud

Concealing manufacturing defects or fabricating clinical data can also feed FCA liability if the government paid for products it would not have covered had it known the truth. The Escobar materiality standard controls: the concealed fact has to be one the government would actually care about when deciding to pay.

Keeping Money You Owe Back

The statute punishes not only companies that take money through fraud but companies that hold onto money they owe. Under 31 U.S.C. § 3729(a)(1)(G), knowingly avoiding an obligation to pay the government triggers “reverse false claim” liability.³

The teeth come from the 60-day overpayment rule. Anyone who receives a Medicare or Medicaid overpayment must report and return it within 60 days of identifying it. Miss that window, and the retained overpayment becomes an “obligation” under the FCA.⁷ For a drug manufacturer, that means an internal audit turning up historical overbilling cannot be quietly shelved. The clock starts the moment the overpayment is identified, and ignoring it creates fresh FCA exposure on top of whatever caused the original error.

What It Costs: Damages and Penalties

FCA liability lands on a company two ways at once.

Every false claim carries a civil penalty adjusted annually for inflation. As of the most recent adjustment, the range runs from $14,308 to $28,619 per claim.⁸ A single marketing campaign or kickback arrangement can generate hundreds of thousands, sometimes millions, of individual prescription claims over several years. The per-claim math alone can eclipse the underlying loss.

On top of those penalties, the company owes treble damages — three times the amount the government actually paid out because of the fraud — plus the government’s litigation costs.³ That is what drives pharmaceutical settlements into the billions.

Most large pharmaceutical resolutions also include a Corporate Integrity Agreement with the HHS Office of Inspector General. These agreements typically run five years and require a compliance officer, external audits, and internal monitoring built to catch repeat conduct. A serious breach can lead to exclusion from federal healthcare programs, which for a company that sells into Medicare and Medicaid is effectively terminal.⁹

How Cases Get Started: Whistleblowers

Most pharmaceutical FCA cases begin with an insider. The statute’s qui tam provisions let a private individual, called a relator, file suit on the government’s behalf. The complaint is filed under seal in federal court and served on the Department of Justice with all supporting evidence, so the company does not know it is under investigation.¹⁰ The initial seal runs at least 60 days, but extensions stretching years are routine in complex drug industry investigations. At the end, the government either intervenes and takes over the case or declines and leaves it to the relator to pursue.

What Whistleblowers Recover

Relators get a fixed share of whatever the government collects. When the government intervenes, that share runs from 15 to 25 percent. When it declines and the relator litigates alone, the share rises to between 25 and 30 percent.¹¹ In pharmaceutical cases, even the minimum share on a nine- or ten-figure recovery is life-changing money.

The Public Disclosure Bar

A relator cannot recycle fraud allegations that are already public. If the same allegations appeared in a federal hearing, a government report or audit, or the news media, the court must dismiss the case unless the relator qualifies as an “original source.”¹¹ That means either disclosing to the government before the public disclosure, or bringing independent knowledge that materially adds to what was already out there and sharing it with the government before filing. Waiting too long after the underlying facts break in public can extinguish the right to sue.

Protection From Retaliation

Employees, contractors, and agents who are fired, demoted, suspended, harassed, or otherwise punished for pursuing an FCA action can sue for reinstatement, double back pay with interest, and special damages including attorney fees.¹¹ These protections reach beyond formal qui tam filings and cover lawful steps to investigate or report potential violations. Retaliation claims must be filed within three years of the retaliatory act.

Filing Deadlines

The FCA gives plaintiffs two deadlines and lets them use whichever is longer. The first is six years from the date of the violation. The second runs three years from the date the responsible government official knew or should have known about the fraud, capped at ten years from the violation itself.¹²

In Cochise Consultancy, Inc. v. United States ex rel. Hunt (2019), the Supreme Court held that a whistleblower may rely on that longer tolling period even when the government declines to intervene.¹³ A relator who discovers pharmaceutical fraud years after it happened may still have up to ten years from the violation to file, depending on when the government first learned the relevant facts.

State False Claims Acts Run Alongside

Federal exposure is only half the picture. A majority of states have their own false claims statutes, many aimed squarely at Medicaid fraud. They tend to track the federal structure — qui tam suits, treble damages, per-claim penalties — and some pay whistleblower shares as high as 50 percent. Because Medicaid is jointly funded, one drug fraud scheme routinely triggers parallel actions, and large settlements often bundle federal and state components together, with state attorneys general resolving their claims alongside the DOJ.

1
United States Department of Justice. False Claims Act Settlements and Judgments Exceed $6.8B in Fiscal Year 2025
2
U.S. Department of Health and Human Services. Fraud and Abuse Laws
3
Office of the Law Revision Counsel. United States Code Title 31 Section 3729 – False Claims
4
Legal Information Institute. Universal Health Services Inc v United States ex rel Escobar
5
Centers for Medicare and Medicaid Services. Off-Label Pharmaceutical Marketing – How to Recognize and Report It
6
Office of the Law Revision Counsel. United States Code Title 42 Section 1320a-7b – Criminal Penalties for Acts Involving Federal Health Care Programs
7
Office of the Law Revision Counsel. United States Code Title 42 Section 1320a-7k – Medicare and Medicaid Program Integrity Provisions
8
Federal Register. Civil Monetary Penalties Inflation Adjustments for 2025
9
Office of Inspector General. Corporate Integrity Agreements
10
The United States Department of Justice. The False Claims Act
11
Office of the Law Revision Counsel. United States Code Title 31 Section 3730 – Civil Actions for False Claims
12
Office of the Law Revision Counsel. United States Code Title 31 Section 3731 – False Claims Procedure
13
Supreme Court of the United States. Cochise Consultancy v United States